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We have previously shown that during muscle pain induced by infusion of hypertonic
saline (HS), concurrent application of vibration and gentle brushing to overlying and
adjacent skin regions increases the overall pain. In the current study, we focused
on muscle-muscle interactions and tested whether HS-induced muscle pain can be
modulated by innocuous/sub-perceptual stimulation of adjacent, contralateral, and
remote muscles. Psychophysical observations were made in 23 healthy participants.
HS (5%) was infused into a forearm muscle (flexor carpi ulnaris) to produce a stable
baseline pain. In separate experiments, in each of the three test locations (n = 10 per
site)—ipsilateral hand (abductor digiti minimi), contralateral forearm (flexor carpi ulnaris),
and contralateral leg (tibialis anterior)—50 µl of 0.9% normal saline (NS) was infused
(in triplicate) before, during, and upon cessation of HS-induced muscle pain in the
forearm. In the absence of background pain, the infusion of NS was imperceptible to all
participants. In the presence of HS-induced pain in the forearm, the concurrent infusion
of NS into the ipsilateral hand, contralateral forearm, and contralateral leg increased the
overall pain by 16, 12, and 15%, respectively. These effects were significant, reproducible,
and time-locked to NS infusions. Further, the NS-evoked increase in pain was almost
always ascribed to the forearm where HS was infused with no discernible percept
attributed to the sites of NS infusion. Based on these observations, we conclude that
intramuscular infusion of HS results in muscle hyperalgesia to sub-perceptual stimulation
of muscle afferents in a somatotopically unrestricted manner, indicating the involvement
of a central (likely supra-spinal) mechanism.
Keywords: normal saline, muscle afferent, somatotopy, muscle pain, hypertonic saline, hyperalgesia,
central sensitization
INTRODUCTION
For most individuals, it is relatively easy to distinguish between innocuous and noxious stimuli.
However, in a subset of individuals afflicted with chronic pain, there is a disturbance of normal
somatosensory function, such that a normally innocuous stimulus can evoke pain, for example, the
emergence of tactile allodynia in patients with sciatica (1). This can have a debilitating impact on
both the individual and society (2, 3).
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Studies using hypertonic saline (HS) infusions have shown a
touch-evoked pain (allodynia) that extends to overlying (4) and
adjacent (5, 6) skin regions. Intramuscular HS administration
produces a deep musculoskeletal pain that often extends or refers
to distal regions (7–9). Repeated intramuscular injections of HS
reveal plastic processes with a decrease in the area and intensity of
local pain and an increase in the expression of referred pain (10)
in addition to the emergence of pain hypersensitivity that extends
bilaterally (11). These complex interactions cannot readily be
explained by changes in peripheral circuitry and appear to mimic
characteristics of chronic pain conditions such as fibromyalgia.
Within such chronic pain conditions, current arguments favor
an explanation based on a central change in, or sensitization
of, the neural function that results in the observed widespread
and diffuse musculoskeletal pain, pressure-pain hypersensitivity,
cutaneous allodynia, and tactile dysesthesia (12–14).
In the current study, a HS infusionmodel was used to examine
whether the interaction previously observed between muscle and
skin (4, 6, 11) can be replicated between adjacent and remote
muscles. We hypothesized that the presence of background
nociceptive activity using HS infusion would produce a state of
central sensitization resulting in an exacerbation of the overall
pain (hyperalgesia) to the application of a normally innocuous
stimulus (normal saline, NS). We also hypothesized that this
effect would occur regardless of whether the NS was infused into
an adjacent or a remote muscle.
METHODS
Twenty-three healthy naïve participants aged 18–28 years
(six females), with no reported history of musculoskeletal or
neurological disorders, were recruited for this study. Participants
were asked to abstain from intensive bouts of exercise for 48 h
preceding the experiment so as not to sensitize the target muscles
(15). Six participants took part in multiple arms of the study
across different experimental sittings (30 experiments total),
the inclusion of these participants in multiple study arms was
random. One participant took part in all arms of the study,
whilst a further five participated in both the contralateral and
remote testing procedures. To minimize the risk of a placebo
effect or familiarization with the protocol, repeat participants did
not undertake experiments in any prescribed order with control
recordings in the absence of HS-infusion (i.e., no-pain) obtained
at the commencement of each separate experiment session across
each of the test locations.
Informed written consent was obtained from each participant
prior to the experiment. This study was approved by the Human
Research Ethics Committee (approval numbers: H9190 and
H13204) of Western Sydney University in accordance with the
revised Declaration of Helsinki.
Participants were comfortably seated in a chair throughout the
experiment. HS and NS were infused using a Syringe Infusion
Pump (Harvard Apparatus, South Natick, Massachusetts, USA)
and a 25G winged infusion set. Importantly, the Syringe Infusion
Pump used for NS-infusion was obscured from sight and did
not include any audible cues. Pain ratings were continuously
recorded using the ADInstruments ResponseMeter connected to
the ADInstruments PowerLab (ADInstruments, Dunedin, New
Zealand). The Response Meter had a slide control, and the pain
scale was divided into ten equal segments within a range of
0 (no pain) to 10 (worst pain). In addition, participants were
asked to verbally report the location of pain during the course
of the experiment.
Infusion of Hypertonic Saline
Across all parts of the study, 5% HS was infused into the belly of
the flexor carpi ulnaris (FCU) muscle of the forearm for∼10min
to establish a stable baseline pain. The muscle belly was palpated
whilst the participant performed light flexion and adduction of
the wrist to identify the boundaries of the FCU muscle. The
needle was inserted∼0.8–1 cm into the center of the muscle belly
at an angle perpendicular to the skin at the site of insertion. The
infusion rate of HS in the FCU varied between subjects (30–175
µl/min) to establish amoderate pain intensity preferably between
4 and 6 (out of 10) on the pain scale. Once a stable baseline pain
was achieved, no further changes were made to the infusion rate.
Infusion of Normal Saline
After a stable baseline pain was maintained for at least a minute,
NS (0.9%) at room temperature was concurrently infused at the
rate of 50 µl/min for 1min per trial (tested in triplicate). This
duration was chosen based on the data collected in a pilot study
which indicated a delay of several seconds before the onset of an
increase in pain levels. The delayed response has been reported in
previous studies (6, 16). The triplicate NS trials were performed
at 1-min intervals.
Participants were asked to continuously rate the overall pain
intensity, and any changes thereof, on the pain scale. Care was
taken to avoid the use of suggestive language with participants
informed that the HS-induced pain could remain the same,
increase or decrease during the co-infusion with NS.
In addition to concurrent HS-NS infusions, NS alone was
infused in triplicate trials prior to the commencement and upon
cessation of HS-evoked pain in all experiments. Typically, the
HS-evoked pain disappeared over a time course of under 10min.
After a 3- to 5-min wait following cessation of pain, NS infusion
was repeated at each site. Collectively,∼450 µl of NS was infused
per muscle.
Part 1: Interactions With Adjacent Muscles
NS was infused into the ipsilateral abductor digiti minimi (ADM)
muscle of the hand to examine potential interactions between
adjacent muscles in response to HS-induced acute muscular
pain. The muscle belly of the ADM was identified by palpation
whilst the participant abducted the fifth digit of their hand. The
infusion needle was inserted to a depth of ∼0.5 cm into the
center of the ADM muscle belly. The ADM muscle was chosen
as it shares the same peripheral innervation (ulnar nerve) as the
HS-infused FCU.
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Part 2: Contralateral Interactions
NS was infused into the belly of the contralateral
FCU muscle of the forearm to test whether the HS-
NS interactions were limited to muscles within the
same nerve territory or spread to contralateral muscles
as well. The needle location and insertion for the
contralateral FCU were identical to the HS-infusion site
described prior.
Part 3: Remote Interactions
NS was delivered to the belly of the tibialis anterior (TA)
muscle of the contralateral leg to determine the spatial extent
of inter-muscle interactions in an acute pain state. The muscle
belly of the TA was identified by palpation during dorsiflexion
of the ankle. The needle was inserted into the middle of the
belly of the TA muscle perpendicular to the skin to a depth
of∼1 cm.
Statistical Analysis
Repeated measures two-way analysis of variance (RM 2-way
ANOVA) was used to compare pain ratings at baseline (HS
infusion alone) with evoked responses (co-infusion of NS and
HS) at each location (adjacent, contralateral, and remote).
Where a significant change (P < 0.05) was found, individual
comparisons were made using Tukey’s multiple comparison
test. The normal distribution of data was confirmed in all
groups using D’Agostino and Pearson omnibus normality test.
Pain scores for the baseline (HS) and co-infusion (HS and
NS) conditions are presented as mean ± standard error of
the mean (SEM) for all parts of the study. Statistical analysis
was performed using GraphPad Prism (version 7.04, La Jolla,
California, USA).
RESULTS
Prior to the induction and following the cessation of HS-evoked
muscle pain, all participants reported NS infusion (50 µl/min)
to be innocuous (i.e., rated as 0 out of 10 on the pain scale) and
imperceptible regardless of the NS infusion site (Figure 1A). The
infusion of 5% HS into the FCU always resulted in a diffuse, deep
pain in the muscle that extended down the medial aspect of the
forearm. This baseline pain remained stable in the absence of NS
co-infusions (Figure 1A) and did not significantly differ between
the different parts of the study (P = 0.66).
At all three test locations (adjacent, contralateral, and remote),
the co-infusion of NS significantly increased the overall pain
in all trials (T1-3, P < 0.0001, Figures 1B–D left-hand panel).
All observed increases in pain scores during co-infusion were
transient and time-locked to the NS-infusion, with the pain
returning to baseline (HS) within 1min of the cessation of
NS co-infusion (example shown in Figure 1A). Further, the
increases in pain scores did not vary in amplitude based on
the location (adjacent, contralateral, and remote) of the NS
co-infusion (P = 0.30).
The pooled mean response of all participants in each part of
the study, with respective HS andHS+NS data points linked, are
shown in the right-hand panel of Figures 1B–D and described
further in the following sections.
Part 1: Interactions With Adjacent Muscles
The infusion of HS into the FCU resulted in a pooled mean
score of 4.3 ± 0.5 (n = 10). When NS was co-infused into
the adjacent ADM in the presence of this background pain,
the pooled mean score increased to 5.0 ± 0.4 (Figure 1B).
This constitutes a pain increase of ∼16% and when comparing
baseline and co-infusion pain scores the increase in pain ratings
was significant [P < 0.0001, F(1,27) = 318.5]. This indicates that
muscle pain can be modulated by low-threshold/sub-perceptual
stimulation of an adjacent muscle.
Part 2: Contralateral Interactions
The infusion of HS into the FCU resulted in a pooled
mean score of 4.3 ± 0.1 (n = 10). The co-infusion of
NS into the contralateral FCU increased this pooled
mean score to 4.8 ± 0.2 (Figure 1C). This represents
a ∼12% increase in the pain scores during co-infusion,
an effect found to be significant [P < 0.0001, F(1,27)
= 156.7]. This demonstrates that muscle pain can
be modulated by normally sub-perceptual stimulation
across contralateral muscles, thereby suggesting a central
(spinal/supra-spinal) phenomenon.
Part 3: Remote Interactions
Within this aspect of the study, participants reported a pooled
mean score of 4.0 ± 0.1 in response to infusions of HS
into the FCU (n = 10). During concomitant infusion of
NS into the contralateral TA, participants reported a pain
increase of 15% with the pooled mean score increasing
to 4.6 ± 0.1 (Figure 1D). A comparison of the baseline
and co-infusion pain scores revealed a significant difference
[P < 0.0001, F(1,27) = 97.84]. The observed interaction between
the site of noxious muscle stimulation and remote innocuous
muscle stimulation alludes to the involvement of a supra-
spinal mechanism.
In Figure 2, triplicate responses for each individual (n = 10
per test location) at all three test sites (n = 90) to transient NS
infusion during HS infusion (i.e., HS + NS) have been plotted
as a function of the baseline pain evoked by HS alone. When
plotted in this manner, all data points fell to the left of the line
of equivalence (x = y or HS = HS + NS) indicating that the NS
infusion evoked a reproducible pain increase across a broad range
(pain scale 1.4–6.7) of baseline pain levels.
When participants were asked about the location of
pain, all participants—except 2 in part 1 and one each
in parts 2–3—ascribed it to the forearm where hypertonic
saline was infused with no discernible percept attributed
to the sites of NS infusion. This was true not only for
HS-evoked pain but also for pain increases during HS-NS
co-infusions. The four subjects who did not ascribe the
pain increase to the HS-infusion site instead ascribed it
to the NS-infusion site. Importantly, these subjects always
reported NS-infusion as imperceptible at the local site under
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FIGURE 1 | Pain intensities in response to HS-infusion and subsequent to transient NS-infusions at various sites across the body. An example raw trace of a
participant’s pain ratings throughout an experimental sitting is shown (A). In the absence of background pain, infusions of NS for 1min (T1, T2, T3 with infusion
time-course shown by the overlying bar) were imperceptible. During baseline HS-induced muscle pain in the FCU, co-infusion of NS (triplicate, left B–D) produced a
reproducible increase in overall pain. Following the cessation of HS infusion and the associated background pain (0 out of 10 on the pain scale), NS trials were once
again imperceptible. In all three sessions, HS pain was generated in the FCU, and the test location for NS infusion was the adjacent ADM muscle (B), the contralateral
FCU (C), or the contralateral TA muscle (D, remote). At each test location, NS co-infusion during HS background pain resulted in a reproducible and significant
increase in overall pain (P < 0.0001, right B–D). The transient pain increase was reproducible across trials at all sites. Significant changes (P < 0.0001, #) were
confirmed between baseline (HS) and co-infusion (HS + NS) using RM 2-way ANOVA.
control and recovery conditions (no HS-pain). This suggests
that NS infusion was almost always nonpainful regardless
of whether there was HS pain or not, but in the presence
of HS pain, the NS co-infusion resulted in hyperalgesia
at the HS site, and this modulation of HS pain was not
somatotopically restricted.
Frontiers in Pain Research | www.frontiersin.org 4 December 2020 | Volume 1 | Article 601544
Dunn et al. Somatotopically Unrestricted Muscle Pain Modulation
FIGURE 2 | Triplicate data points for each participant during HS-NS
co-infusion plotted as a function of baseline pain. When triplicate responses
from each participant at each location (n = 10 per location, total n = 90) to NS
infusion during HS infusion (HS + NS) are plotted as a function of baseline pain
(i.e., HS alone) all data points fall to the right of the line of equivalence (x = y or
HS = HS + NS). This indicates that the NS infusion evoked a reproducible
effect between trials and across all test sites and over a broad range of
baseline pain levels.
DISCUSSION
The current study has provided evidence that muscle pain can
be modulated (hyperalgesia) by sub-perceptual stimulation of
muscle afferents in a somatotopically unrestricted manner. This
finding not only builds upon the previous observation that an
intramuscular HS infusion can result in allodynia in the overlying
and adjacent skin regions (4, 6, 17) but the spatial extent of
this modulation, spanning several spinal segments, suggests the
involvement of a central, likely supra-spinal, mechanism.
The sub-perceptual nature of repeated intermittent NS
infusions (50 µl over 1min) under control (no HS-pain)
condition suggests that localized muscle distension does not
activate the nociceptors (18) but may activate low-threshold
stretch-sensitive receptors within the muscle. In this respect,
these weak mechanical stimuli resemble the inability of
weak (micro) intraneural electrical stimulation to produce a
discernible pain sensation at recording sites dominated bymuscle
spindles (19, 20).We have also previously shown that intradermal
infusions of NS (50 µl/min for 2min) do not produce a
percept (5).
The conversion of the sub-perceptual NS stimulus to one
that enhances pain, during HS infusion in the FCU muscle,
is unlikely to be due to peripheral sensitization given the
anatomical separation (forearm vs. hand, >15 cm) and the small
volume of intermittently infused NS. Likewise, the increase
in pain evoked by NS-infusion into the contralateral forearm
is more consistent with a central involvement. Furthermore,
the interaction between the FCU and the contralateral TA
suggests that the central involvement likely extends to supra-
spinal structures. Assertions as to the exact location of this
central involvement cannot be resolved by this study, but the
acute/short-lasting and reversible nature of these interactions
do suggest that the requisite circuitry may already be present,
and thus an elaborate anatomical reorganization need not be
necessary for these to occur.
The broad-ranging muscle-muscle interactions observed
here appear to be in marked contrast to the somatotopically
constrained interactions observed in the skin; for example,
the confinement of secondary hyperalgesia to the region
immediately surrounding intradermal capsaicin injection
(21–23) or the inability of microstimulation of large-diameter
mechanoreceptors innervating a skin region beyond the site of
secondary hyperalgesia to produce a painful percept (16).
The effects observed in the current study aremost likely driven
by a transient and reversible episode of central sensitization
(increased excitability and synaptic efficacy of central nociceptive
pathways) (24) in response to the HS-induced muscle pain.
The HS infusion alone was run for ∼10min prior to the
commencement of NS co-infusion, and this may have resulted
in a state of central sensitization. Indeed, the clinical correlates of
central sensitization (25, 26) are apparent in a HS-infusion model
with hyperalgesia and allodynia reported in this and previous
work (4, 6, 11, 17).
The generalized modulation of the exacerbated pain response
at the HS-induced muscle site during NS-infusion in the
adjacent, contralateral, and remote muscles is noteworthy and
warrants further study using more quantitative measures
of pain localization than verbal reporting. Further, the
quality and temporal characteristics of this hyperalgesia
need further investigation. In addition to the prerequisite
of ongoing nociceptive input (HS infusion), we observed
that the onset of NS-evoked increase in pain tended to be
delayed by several seconds, which suggests a possible need for
temporal summation.
Previous findings in humans have shown that repeated
intramuscular HS injections in the TA result in a pressure-
pain hypersensitivity developing across both the ipsilateral and
contralateral TA muscles (11). Further, it has been shown
in animals that a unilateral forelimb injury can produce
sensory perturbations in the contralateral limb (27). In the
case of intramuscular HS, the evidence for centralized effects
necessitates the need for control data collection prior to any
HS administration and warrants an investigation into other
commonly used pain models.
In the current study, the co-infusion of sub-perceptual NS
resulted in increased HS-pain (i.e., hyperalgesia). In HS and
other experimental models as well as chronic pain conditions,
tactile and thermal stimuli can produce allodynia (pain to a
normally nonpainful stimulus) and hyperalgesia (increased pain
from a painful stimulus) (1, 4, 6), but paradoxically, these
modulatory stimuli—both painful and nonpainful—can also
reduce pain with slow gentle brushing of the skin shown to
reduce cutaneous heat pain (28). Conditioned pain modulation is
a well-recognized phenomenon in which a painful stimulus can
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be inhibited by a second painful stimulus applied to a different
body site (i.e., pain inhibits pain) (29–31). The underlying
mechanisms are not fully understood but likely involve a complex
interplay between excitatory and inhibitory circuits in the central
nervous system.
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